Evgen Pharma Share Discussion Threads

[bumpa33] 04/4/2021 10:47

Diamond is the new Gnome eh?

Suppose the thread would be boring without at least one idiot.

[bumpa33] 04/4/2021 10:41

mm - no not yet, over 80’s only and hospital staff, teachers etc. Probably be around 2023 by the time i get it.

[bocker01] 03/4/2021 22:41

Quite so Money. Interesting look back there OT. An eye opener.

[moneymunch] 03/4/2021 22:00

Anyways, if Prof Chalmers delivers negative news, then a drop of 37% would take the share price down to Evgen's £13m cash in the bank, and with so much potential material news that Huw could deliver thereafter, expected from the rest of the pipeline, then the share price should recover very quickly imho, and if Prof Chalmers delivers positive news, then the upside could be multiples of the current share price Gla :-)

[on target] 03/4/2021 21:58

Indeed, SNG's phase 2 trial, consisting at that time of 100 patients..
Friday 17/7 shareprice was 35p with a market cap of £52m
Monday 20/7 - positive results of trial announced. Reached a high of 239p (mcap £356m) and closed at 189p (£282m).
So SNG market cap increased by no less than £300m on their phase 2 trial result on 100 patients.

[moneymunch] 03/4/2021 21:52

Lol bocker, well if he hadn't got his lab assistant to close down the old thread, we could have continued the pointless bickering that he obviously revelled in, as is the case with most hypocrites who are the main protagonists and instigators because the only opinion that matters is his own, that's the usual way of anyone with a sanctimonious self-righteous know it all character, and the very reason why his lab assistant gave reason for closing down the the old thread...ha ha ha ha...you couldn't make it up...Gl :-)

[moneymunch] 03/4/2021 20:52

Not too sure about 50% down, otherwise that would take Evgen's Market Cap below the amount of cash they have in the bank c£13m....and i reckon if Prof Chalmers reports postive phase 2/3 efficacy data, then the share price will rise far higher than 50% imho....just remind me again on how high SNG's share price rose after encouraging phase 2 data ???

[moneymunch] 03/4/2021 20:41

The only one's with the answers here are those who have access to the clinical trial data such Prof Chalmers et al. ;-)

ps Bumpa, have you had your jab yet in Spain? 43% of the UK have now been vaccinated and only 11% plus of the entire European population have had their's, and most countires there are now approaching 3rd lock down, whereas here in the UK numbers for infection and hospitalisation is at an all time low!!!??? I had the AZ jab, and proud to have it, i've got a Dutch mate who wouldn't touch it with a barge pole...30 people here have had the blood clot and unfortunetly 7 have died but that's from over 18m AZ jabs....yet 1 in 6 Covid patients run the risk of blood clots.....my holiday plans to France and Spain etc are on hold for the moment. ;-I

[diamondstar1] 03/4/2021 20:33

I will ignore the last few posts from Bumpa! I am neutral on Evgen - I have no long or short positions. I am not into massive ramping like many other people here (or deramping either). Just sharing some honest thoughts on Evgen. I believe that Evgen made the right decision to start the trial in Dundee - because it is grant funded. However, forward risks are still high - could be a 50% up with positive interim analysis or 50% down with premature termination of the trial due to lack of efficacy.

[moneymunch] 03/4/2021 20:29

No shortage of potential patients for SFX-01's Covid/ARDS trial it would semm ...Covid or not Covid!!!



Pneumonia is a form of acute respiratory infection that is most commonly caused by viruses or bacteria. It can cause mild to life-threatening illness in people of all ages, however it is the single largest infectious cause of death in children worldwide.

Pneumonia killed more than 808,000 children under the age of 5 in 2017, accounting for 15% of all deaths of children under 5 years. People at-risk for pneumonia also include adults over the age of 65 and people with preexisting health problems.

The lungs are made up of small sacs called alveoli, which fill with air when a healthy person breathes. When an individual has pneumonia, the alveoli are filled with pus and fluid, which makes breathing painful and limits oxygen intake. These infections are generally spread by direct contact with infected people.

[bumpa33] 03/4/2021 20:24

Apologies, in no mood for idiots, can’t get that Socrates quote out of my head “I know that I’m intelligent because I know that I know nothing”...

[moneymunch] 03/4/2021 19:50

 0

There's a 28 day assessment on each patient following the 14 days of dosing, that's why the DSMB were able to assess the first 60 patients recruited to the trial, and prelimanary efficacy data will be available for the first 100 during Q2...Gl ;-)

Background to the Trial 1

STAR-COVID 19 TRIAL

TRAINING BACKGROUND AND OVERVIEW

Community-acquired pneumonia is a leading cause of morbidity and mortality in the UK

There have been no new therapies for managing pneumonia since advent of antibiotics in 1950s

The global pandemic caused by novel coronavirus SARS-CoV-2, has highlighted the need for new drugs to treat pneumonia

Development of anti-inflammatory therapies that prevent late stage complications is needed

Such therapies are likely to be efficacious for a range of acute respiratory infections, including COVID-19

Patients with pneumonia and suspectedCOVID-19 are eligible for this trial. Patients do not require a positive COVID-19 test to be eligible

....................

Background to the Trial 2


The nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) is part of the human natural defence against inflammatory and oxidative stress such as the inflammation that occurs during a severe viral infection

In animal studies, pharmacological activation of Nrf2 reduces the severity of acute respiratory distress syndrome (ARDS)

SFX-01(stabilised sulforaphane), a drug developed by EvgenPharma, is an activator of Nrf2

SFX-01 has been tested in over 130 subjects in clinical trials and is well tolerated with main side effects being GI related and ameliorated by taking after food

In this study one 300mg capsule of SFX-01 is taken orally per day for 14 days

This is the first study of the effect of SFX-01 in humans with acute respiratory infections at risk of developing ARDS

.......................

The trial will test the following hypothesis:

Treatment with SFX-01 in addition to standard care will be superior to placebo plus
standard care in achieving improved clinical status in patients initially hospitalized with community acquired pneumonia (including patients investigated for suspected COVID19 infection).

.........................

Primary objective:

To evaluate the clinical efficacy of SFX-01 compared to placebo on top of standard care in adult patients initially hospitalized with community acquired pneumonia.Outcome measure:7 point ordinal scale measured on Day 15.

Secondary Objectives:

Evaluate the clinical efficacy of SFX-01 relative to standard care in adult patients hospitalized with suspected COVID-19

Evaluate the safety of the intervention through 28 days of follow-up as compared to the control arm

Outcome measures:

Cumulative incidence of serious Adverse events (SAEs)

Discontinuation or temporary suspension of treatment

..............................

Exploratory objectives (All sites)

Biofire analysis of nasal swab or sputum sample

Subanalysis of outcomes according to the causative pathogen

Exploratory objectives (TAYSIDE ONLY)

Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells

Neutrophil functional studies in isolated cells

Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood

[diamondstar1] 03/4/2021 19:23

Bumpa33.... you seem to be a cut and paste expert. Have you even managed a patient with ARDS or even designed a clinical trial?

[bumpa33] 03/4/2021 19:23

What will they have then - a runny nose, headache perhaps?




Trial aims:

We think that SFX-01 may help people with pneumonia by reducing the amount of inflammation and damage in their lungs. We want to know if taking SFX-01 shortens your time in hospital. We also want to find out if you’re less likely to need oxygen for a long period or put on a ventilator and if you’re more likely to recover.

[diamondstar1] 03/4/2021 19:18

The STAR trial is supposed to assess the impact on reducing severity or preventing the onset of ARDS. So, not all patients will have ARDS on inclusion into the study.

[bumpa33] 03/4/2021 19:17

Here, try this for a start on ARDS





Note the causes below, rather more than ‘just’ pathogens...


Causes[edit]
There are direct and indirect causes of ARDS depending whether the lungs are initially affected. Direct causes include pneumonia (including bacterial and viral), aspiration, inhalational lung injury, lung contusion, chest trauma, and near-drowning. Indirect causes include sepsis, shock, pancreatitis, trauma (e.g. fat embolism), cardiopulmonary bypass, TRALI, burns, increased intracranial pressure.[10] Fewer cases of ARDS are linked to large volumes of fluid used during post-trauma resuscitation.[11]

[bumpa33] 03/4/2021 18:59

If you can’t grasp the simple stuff, maybe stick to engine oil companies.

[bumpa33] 03/4/2021 18:58

You’re not preventing ARDS, you are treating and alleviating the symptoms of it ffs.

And btw, It is not Neuroblastoma (which originates in the adrenal glands and usually affects young children), it is glioblastoma and glioma (which are brain cancers)

[diamondstar1] 03/4/2021 18:52

Moneymunch - thanks for this valuable information. So, it’s a sink or float situation with the upcoming interim analysis.

Yet, the patient population is potentially very heterogeneous - you may get some with background viral infections (eg COVID-19, influenza, etc) and bacterial pneumonias (staph, strep etc). Problem is Regulatory pathway is not clear to me- how do you get a drug approved for prevention of ARDS with various underlying pathogenic causes? I’m really not sure what FDA and EMEA will ask for - in terms of a pivotal Ph3 design.